Skip to main content

Table 2 Association of RBM3 IHC results and clinico-pathological features of esophageal squamous cell carcinoma samples

From: Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome

 

RBM3 immunohistochemistry

 

Analyzable, n

Low, %

High, %

P value

All cancers

226

40.71

59.29

 

Age group

 < 65 years

86

46.51

53.49

0.178

 > 65 years

139

37.41

62.59

Sex

 male

160

41.88

58.13

0.6362

 female

65

38.46

61.54

Tumor stage

 pT1

40

17.5

82.5

0.0061

 pT2

46

41.3

58.7

 pT3

126

46.83

53.17

 pT4

14

50

50

UICC stage

 I

55

23.64

76.36

0.0213

 II

57

45.61

54.39

 III

102

47.06

52.94

 IV

10

50

50

Tumor grading

 G1

3

33.33

66.67

0.3216

 G2

141

44.68

55.32

 G3

81

34.57

65.43

 G4

0

0

0

Resektion margin

 R0

168

39.29

60.71

0.0717

 R1

47

40.43

59.57

 R2

9

77.78

22.22

Lymph node metastasis

 N0

100

35

65

0.0192

 N1

55

32.73

67.27

 N2

40

55

45

 N3

29

58.62

41.38

Distant metastasis

 M0

216

59.72

40.28

0.366

 M1

9

44.44

55.56